Mr. Reali resigned April 4, and Anthony Bihl was appointed interim CEO, according to an April 3 SEC filing from Bioventus. Mr. Bihl has more than 35 years of experience in the medtech industry, according to an April 5 company news release.
Bioventus is currently seeking a permanent CEO. Mr. Reali’s departure comes just over a month after the company said its $450 million acquisition of CartiHeal may not happen.
